PuSH - Publication Server of Helmholtz Zentrum München: Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults : Results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Wendtner, C.-M. ; Abdel-Rahman, S.* ; Baumert, J.J.* ; Falk, M.H.* ; Krych, M.* ; Santl, M.* ; Hiddemann, W.* ; Issels, R.D.

Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults : Results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.

Eur. J. Cancer 37, 1609-1616 (2001)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

The efficacy of thermochemotherapy in adult patients with primary, recurrent or inadequately resected non-metastatic high-risk soft-tissue sarcomas (STS) was assessed. 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation. The objective response rate was 16% and at a median follow-up time of 57 months, the 4-year estimated rates of local failure-free survival (LFFS), distant metastasis-free survival (DMFS), event-free survival (EFS) and overall survival (OS) were 59% (95% confidence interval (CI) 45–73%), 59% (95% CI 44–73%), 26% (95% CI 14–38%) and 40% (95% CI 27–53%), respectively. OS was in favour of patients responding to neoadjuvant treatment (P=0.073). In comparison to a preceding phase II study including pre- and postsurgical thermochemotherapy (RHT-91), at a 4-year follow-up the RHT-95 study cohort showed an inferior LFFS rate (P=0.027), but this did not affect DMFS (P=0.558) or OS (P=0.126). Hence, postsurgical thermochemotherapy seems critical for local tumour control without affecting survival.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

0.000